Ibrutinib already had 5 indications for the treatment of CLL and now has received its 6th for use in combination with rituximab as a frontline therapy.
This latest approval was based on the results from ECOG-ACRIN’s E1912 clinical trial that showed that ibrutinib alone or in combination with rituximab was superior to FCR in younger fit previously untreated patients.
The data showed superior progression-free survival in both ibrutinib arms, and that there was little difference in those two non-chemo therapies.
The good news is that now there are two approved ibrutinib options to consider when treating CLL, both with very similar efficacy.
Here is Medscape on the news where I am extensively quoted: https://www.medscape.com/viewarticle/929181